The price of FibroGen Inc (NASDAQ: FGEN) closed at $1.85 in the last session, up 1.65% from day before closing price of $1.82. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 1323048 shares were traded. FGEN stock price reached its highest trading level at $1.9000 during the session, while it also had its lowest trading level at $1.7250.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at FGEN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.54 and its Current Ratio is at 1.74.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2023, Downgraded its rating to Underperform and sets its target price to $2 from $4 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 01 when Henderson Jeffrey William sold 2,000 shares for $1.03 per share. The transaction valued at 2,060 led to the insider holds 28,866 shares of the business.
Henderson Jeffrey William sold 2,000 shares of FGEN for $3,820 on Aug 04. The Director now owns 30,866 shares after completing the transaction at $1.91 per share. On Jul 11, another insider, Henderson Jeffrey William, who serves as the Director of the company, sold 2,000 shares for $2.69 each. As a result, the insider received 5,380 and left with 32,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FGEN now has a Market Capitalization of 178.00M and an Enterprise Value of 144.27M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.17. Its current Enterprise Value per Revenue stands at 1.07 whereas that against EBITDA is -0.46.
Stock Price History:
Over the past 52 weeks, FGEN has reached a high of $23.53, while it has fallen to a 52-week low of $0.33. The 50-Day Moving Average of the stock is 1.2791, while the 200-Day Moving Average is calculated to be 3.7942.
Shares Statistics:
According to the various share statistics, FGEN traded on average about 2.69M shares per day over the past 3-months and 2.88M shares per day over the past 10 days. A total of 94.17M shares are outstanding, with a floating share count of 91.65M. Insiders hold about 6.80% of the company’s shares, while institutions hold 71.43% stake in the company. Shares short for FGEN as of Jan 31, 2024 were 13.5M with a Short Ratio of 5.01, compared to 13.98M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 13.73% and a Short% of Float of 18.09%.
Earnings Estimates
The company has 2 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.42 and a low estimate of -$0.43, while EPS last year was -$0.7. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.31 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$2.36 and -$2.76 for the fiscal current year, implying an average EPS of -$2.63. EPS for the following year is -$1.28, with 3 analysts recommending between -$1.08 and -$1.56.
Revenue Estimates
According to 2 analysts, the current quarter’s revenue is expected to be $38.9M. It ranges from a high estimate of $40.23M to a low estimate of $37.57M. As of the current estimate, FibroGen Inc’s year-ago sales were $34.37M, an estimated increase of 13.20% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $38.78M, an increase of 21.80% over than the figure of $13.20% in the same quarter last year. There is a high estimate of $40.84M for the next quarter, whereas the lowest estimate is $36.72M.
A total of 3 analysts have provided revenue estimates for FGEN’s current fiscal year. The highest revenue estimate was $173M, while the lowest revenue estimate was $158.18M, resulting in an average revenue estimate of $164.01M. In the same quarter a year ago, actual revenue was $140.37M, up 16.80% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $162.3M in the next fiscal year. The high estimate is $165M and the low estimate is $158.15M. The average revenue growth estimate for next year is down -1.00% from the average revenue estimate for this year.
